Xeomin (incobotulinumtoxinA) coverage
Customize your policy alerts
Sign up for eocco Policy M-0241 alerts
Get alerted when Policy M-0241 changes without checking for updates manually.
Monitor payer policy activity
Policy governing prior authorization, dosing limits, indications, and renewal criteria for Xeomin (incobotulinumtoxinA) for intramuscular, intradetrusor, intradermal, and intraglandular use for covered members.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Initial Therapy (Indication-specific)
Covered when ALL of the following universal criteria are met AND the indication-specific criteria below are satisfied.
FDA approved indication
FDA approved indication
Compendia recommended indication
Compendia recommended indication
Compendia recommended indication
Compendia recommended indication
FDA approved or compendia recommended depending on subgroup
Compendia recommended indication (prior authorization validity may not be renewed)
inv-02: Renewal Therapy
Renewal allowed when ALL of the following are met:
See examples of unacceptable toxicity in policy
Evidence of disease response required
Evidence of disease response required
inv-03: Blepharospasm
Covered when improvement is demonstrated for blepharospasm:
inv-04: Cervical Dystonia
Covered when ALL of the following are met for cervical dystonia:
inv-05: Upper Limb Spasticity
Covered when improvement is demonstrated for upper limb spasticity:
inv-06: Severe Primary Axillary Hyperhidrosis
Covered when ALL of the following are met for severe primary axillary hyperhidrosis:
inv-07: Chronic Migraine Prophylaxis
Covered when ALL of the following are met for prophylaxis of chronic migraine:
inv-08: Neurogenic Detrusor Overactivity and Overactive Bladder
Covered when ALL of the following are met for bladder indications:
Urodynamic confirmation required at initiation
inv-09: Chronic Sialorrhea
Covered when objective reduction is demonstrated for sialorrhea and dosing adheres to weight-based or adult recommendations:
inv-10: General coverage condition
Covered when diagnosis matches one of the listed ICD-10 codes and applicable billing rules/LCDs are followed
Subject to CMS policy applicability
Prior authorization is required for Xeomin (incobotulinumtoxinA). Initial prior authorization validity is 6 months (180 days), and renewals are valid for 12 months (365 days) thereafter unless otherwise specified. Note that for the Ventral Hernia indication, prior authorization validity may not be renewed.
The policy recommends a conservative upper limit for most treatment sessions. The recommended maximum cumulative dose is 400 Units per treatment session, and doses exceeding this amount are not recommended except where explicitly noted (for example, the Ventral Hernia preoperative regimen is an exception).
Medicare policy may impose additional or superseding requirements. Applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) must be followed where relevant; the policy content here is intended for non‑Medicare determinations and CMS NCD/LCD/LCA rules may add or modify requirements. The CMS coverage search tool is referenced for locating current Medicare guidance.
Billing must meet the policy's dual coding requirements to be payable. Primary G and M procedure codes require a secondary G or I code in order for the claim to be payable; claims that fail this dual coding requirement may be denied.
Coding
| HCPCS Unit | Policy lists maximum units per dose and over time by indication (e.g., Cervical Dystonia 200 units; Upper Limb Spasticity 400 units; Ventral Hernia 500 units; etc.) |
| J0588 | Injection, incobotulinumtoxin a, 1 unit; 1 billable unit = 1 unit |
| 00259-1605-xx | Xeomin 50 unit powder for injection; single-dose vial |
| 00259-1610-xx | Xeomin 100 unit powder for injection; single-dose vial |
| 00259-1620-xx | Xeomin 200 unit powder for injection; single-dose vial |
| G24.3 | Spasmodic torticollis |
| G24.5 | Blepharospasm |
| G25.89 | Other specified extrapyramidal and movement disorders |
| G35.A | Relapsing-remitting multiple sclerosis |
| G35.B0 | Primary progressive multiple sclerosis, unspecified |
| G35.B1 | Active primary progressive multiple sclerosis |
| G35.B2 | Non-active primary progressive multiple sclerosis |
| G35.C0 | Secondary progressive multiple sclerosis, unspecified |
| G35.C1 | Active secondary progressive multiple sclerosis |
| G35.C2 | Non-active secondary progressive multiple sclerosis |
| Primary G and M codes | Require a secondary G or I code in order to be payable |
Provider Actions & Requirements
Prior authorization validity and renewal period
Prior authorization is required. Initial authorizations are valid for 6 months (180 days); renewals may be provided every 12 months (365 days) thereafter unless otherwise specified. Note that prior authorization validity may NOT be renewed for the Ventral Hernia indication.
Prior authorization applies to J0588 and vial NDCs
Submit prior authorization requests for Xeomin using HCPCS code J0588 (Injection, incobotulinumtoxinA, 1 unit). When applicable, reference the specific Xeomin vial NDC(s): 00259-1605-xx (50 unit), 00259-1610-xx (100 unit), or 00259-1620-xx (200 unit).
NQTL-informed prior authorization considerations
Prior authorization design was informed by the NQTL factor checklist; PA may be applied based on indication, safety/efficacy, and drug cost. The checklist notes that potential for misuse/abuse was not a priority for PA design.
Required prior medication trials (document failures)
For several indications, members must have documented trials and failures of specified prior medications before coverage is approved. Examples include trials of two oral agents for chronic migraine prevention and failures of two medications (antimuscarinic or beta-adrenergic classes) for bladder indications.
- Chronic migraine: failed at least an 8-week trial of any two oral preventive medications or prior CGRP antagonist treatment (per policy).
- Neurogenic detrusor overactivity / OAB: failed a ≥1 month trial of two medications from antimuscarinic or beta-adrenergic classes.
- Severe primary axillary hyperhidrosis: failed ≥1 month trial of a topical agent.
Continue prophylactic modalities with Xeomin for chronic migraine
When treating chronic migraine, the member should continue other prophylactic interventions (for example, trigger avoidance, pharmacotherapy, behavioral therapy, neuromodulation, physical therapy) alongside Xeomin as part of comprehensive management.
No explicit step therapy rules present
The policy contains no explicit step therapy ordering or sequencing rules beyond documented prior therapy failures; there are no additional step therapy directives in these sections.
Document baseline severity with validated migraine tool
Physicians must document baseline disease severity for chronic migraine using an objective measure/tool (e.g., HIT-6, monthly headache day [MHD], MIDAS, MPFID) as part of the prior authorization record.
Provide objective outcome measures by indication
Prior authorization and renewal requests must include objective outcome documentation demonstrating improvement specific to the treated indication (e.g., reduced eyelid spasm frequency/severity for blepharospasm; decreased pain and improved head position for cervical dystonia; validated tone scales for upper limb spasticity; reduced sweat production and ADL improvement for hyperhidrosis; decreased headache frequency/intensity and functional improvement for chronic migraine; reduced incontinence episodes and periodic PVR assessment for bladder indications; decreased saliva production for sialorrhea).
NQTL checklist factors used to design PA
An NQTL checklist influenced PA design; factors explicitly considered include indication, safety and efficacy, potential for misuse/abuse (not a priority), and drug cost.
- Factors listed: Indication; Safety and efficacy; Potential for misuse/abuse (PA not a priority); Cost of drug.
Deny if FDA-labeled contraindications or active injection-site infection present
Do not approve or bill Xeomin if the member has any FDA-labeled contraindication (e.g., hypersensitivity to any botulinum toxin product or excipients) or if there is an active infection at the proposed injection site; concurrent treatment with another botulinum toxin is also a contraindication to coverage.
Requests exceeding 400 Units per session may be denied
Requests exceeding the recommended maximum cumulative dose of 400 Units per treatment session may be denied unless the request is for the Ventral Hernia indication, which is an exception to the 400-Unit limit.
Dual coding requirement — include required secondary code
Claims using primary G and M procedure codes require a secondary G or I code to be payable; absence of the required secondary code may result in claim denial as not payable.
Initial Therapy Criteria
inv-40: Initial therapy requirements
Initial therapy requires meeting universal criteria plus indication-specific requirements and any required prior medication trials or diagnostic confirmation.
Document medication names and trial durations
inv-41: Initial dosing by indication
Initial and indication-specific dosing recommendations:
Pediatric upper limb dosing and limb-specific limits provided in Dosage/Administration
inv-42: PA considerations
Prior authorization considerations informed by NQTL checklist
Continuation & Renewal Criteria
inv-43: Continuation Therapy
Criteria to continue therapy on renewal
Examples of unacceptable toxicity include toxin spread symptoms, serious hypersensitivity, corneal exposure/ulceration, ectropion for blepharospasm.
inv-44: Continuation Therapy / Repeat dosing intervals
Maintenance dosing frequency guidance for repeat treatments:
Localization techniques recommended where appropriate
Step Therapy
| Indication | Required prior therapy failures | Notes |
|---|---|---|
| Neurogenic detrusor overactivity (urodynamic-confirmed) | Failure of a ≥1 month trial of two medications from antimuscarinic or beta-adrenergic classes | Urodynamic confirmation required |
| Overactive bladder (OAB) | Failure of a ≥1 month trial of two medications from antimuscarinic or beta-adrenergic classes | Symptoms of urge urinary incontinence/urgency/frequency must be present |
| Severe primary axillary hyperhidrosis | Failure of a ≥1 month trial of a topical agent (e.g., 20% aluminum chloride, glycopyrronium, etc.) | Plus history of medical complications or significant functional impairment impacting ADLs/work/social life |
| Chronic migraine prophylaxis | Either failed at least an 8-week trial of any two oral preventive medications OR prior treatment with a CGRP antagonist | Also requires documentation of baseline disease severity and continued use of prophylactic modalities |
| Indication | Requirement | Notes |
|---|---|---|
| Chronic migraine prophylaxis | Member must continue utilization of prophylactic intervention modalities (e.g., avoiding triggers, pharmacotherapy, behavioral therapy, neuromodulation, physical therapy) | Physician must document baseline disease severity with an objective tool (e.g., HIT-6, MHD, MIDAS, MPFID); other causes of headache ruled out |
Quantity Limits
Definitions & Measurement Tools
Site of Care & Procedure Guidance
Use localization techniques (EMG/nerve stimulation/ultrasound) in office
For office-based injections, localization of the involved muscles is recommended using electromyographic guidance, nerve stimulation, or ultrasound where appropriate.
- Localization techniques: EMG, nerve stimulation, or ultrasound.
Background
IncobotulinumtoxinA (Xeomin) is administered by injection and may be given via intramuscular, intradetrusor, intradermal, or intraglandular routes depending on the treated indication. It is used across multiple neurologic and regional indications including cervical dystonia, upper limb spasticity, chronic migraine prophylaxis, axillary hyperhidrosis, sialorrhea, and bladder indications, with dosing and administration details varying by indication.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.